BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (BCRX)

CUSIP: 09058V103

Q1 2026 13F Holders as of 31 Mar 2026

Security type / class
Equity / COMMON STOCK
Total 13F shares
249,057,886
Total 13F value
$2,370,690,957
Holder snapshot 6 visible 7 signals
Share change
+35,818,944
Put/Call ratio
45%
SEC-reported price per share
$9.52
Number of holders
301
Value change
+$366,371,276
Number of buys
182
Open additional details 1 more signal available
Number of sells
116
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
249,150,204

Security key

09058V103

Report period

Q1 2026

Institutions

301

Top holders

10

BCRX full security history Ownership snapshot Full 13F holder table Previous quarter: Q4 2025 BIOCRYST PHARMACEUTICALS INC SEC filings BIOCRYST PHARMACEUTICALS INC company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of BCRX - BIOCRYST PHARMACEUTICALS INC - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BlackRock, Inc.
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F 13D/G 3/4/5 Lead comparable stake: 8.4% 13D/G row: BlackRock, Inc. Showing 1-6 of 15 holder rows.

Quick read

BlackRock, Inc. leads the comparable SEC ownership view at 8.4%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership Top 5
BlackRock, Inc. 8.4%
RA CAPITAL MANAGEMENT, L.P. 7.3%
James E. Flynn 6.8%
VANGUARD CAPITAL MANAGEMENT LLC 5.2%
STATE STREET CORP 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
8.4%
from 13D/G
$164,874,767
21,137,791 shares
 — 31 Dec 2025
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G
Company
13F 13D/G
7.3%
from 13D/G
$123,452,051
15,827,186 shares
 — 31 Dec 2025
James E. Flynn
13D/G
Deerfield Mgmt, L.P.
13D/G
6.8%
$109,278,420
14,341,000 shares
 +$16,550,640 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC
13D/G
Vanguard Capital Management
13D/G
5.2%
$123,390,357
12,961,172 shares
 $0 31 Mar 2026
STATE STREET CORP
13D/G 13F
STATE STREET CORPORATION · Company
13D/G 13F
4.9%
$114,880,668
12,208,360 shares
 +$10,681,752 31 Mar 2026
Avoro Capital Advisors LLC
13D/G
13D/G
4.2%
$71,514,000
8,700,000 shares
 $0 31 Mar 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
301
Shares
249,057,886
Rows available
301
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders
274
Q1 2026 holders
301
Holder diff
27
Investor Q4 2025 Shares Q1 2026 Shares Share Diff Share Chg % Q4 2025 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .